Background: Although clinical reports have suggested a relationship between systemic infections and multiple sclerosis (MS) relapses, MRI evidence supporting an association is conflicting. Here we evaluated the temporal relationship between upper respiratory infections (URIs) and MRI activity in relapsing-remitting (RR) MS. Methods: We combined individual data on URI with data on active lesions in pre-scheduled MRI examinations performed every 4 weeks for 28 weeks in 69 patients. A 4-week at-risk (AR) period started, by definition, 1 week before the onset of a URI. We recorded the relationship between the number of active lesions in each MRI with (1) the number of days of AR time in the immediately preceding 4-week period and (2) the number of days passed since the onset of a preceding URI. Results: Average MRI lesions/day showed no difference between AR (0.0764) and not-AR (0.0774) periods. The number of lesions in 483 pre-scheduled MRI examinations did not correlate with the AR proportion in the prior 4-week period (rho = -0.03), and time from URI onset did not correlate with lesion number on the next MRI examination (rho = 0.003). Conclusion: The occurrence of a URI did not increase the risk of MRI activity evaluated in an adjacent 4-week window in RRMS.

Keywords:
Multiple sclerosis, Relapsing-remitting, Relapse, MRI, Upper respiratory infection, Environmental factor
1.
Sibley WA, Bamford CR, Clark K: Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-1315.
2.
Andersen O, Lygner PE, Bergström T, Andersson M, Vahlne A: Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 1993;240:417-422.
3.
Panitch HS: Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994;36(suppl):S25-S28.
4.
Edwards S, Zvartau M, Clarke H, Irving W, Blumhardt LD: Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:736-741.
5.
Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, et al: Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125:952-960.
6.
Correale J, Fiol M, Gilmore W: The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006;67:652-659.
7.
Rovaris M, Comi G, Ladkani D, Wolinsky JS, Filippi M: Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003;24:75-81.
8.
Bech E, Lycke J, Gadeberg P, Hansen HJ, Malmeström C, Andersen O, et al: A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002;58:31-36.
9.
Andersen O: Restricted dissemination of clinically defined attacks in an MS incidence material. Acta Neurol Scand Suppl 1980;77:1-70.
10.
Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
11.
Isaac C, Li DK, Genton M, Jardine C, Grochowski E, Palmer M, et al: Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988;38:1511-1515.
12.
Weiner HL, Guttmann CR, Khoury SJ, Orav EJ, Hohol MJ, Kikinis R, et al: Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol 2000;104:164-173.
13.
Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, et al: Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990;113:1477-1489.
14.
Koziol JA, Wagner S, Sobel DF, Slivka LS, Romine JS, Sipe JC, et al: Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2001;22:284-291.
15.
Meier DS, Balashov KE, Healy B, Weiner HL, Guttmann CR: Seasonal prevalence of MS disease activity. Neurology 2010;75:799-806.
16.
Sibley WA, Foley JM: Infection and immunization in multiple sclerosis. Ann N Y Acad Sci 1965;122:457-466.
17.
Kriesel JD, White A, Hayden FG, Spruance SL, Petajan J: Multiple sclerosis attacks are associated with picornavirus infections. Mult Scler 2004;10:145-148.
18.
Kneider M, Bergström T, Gustafsson C, Nenonen N, Ahlgren C, Nilsson S, et al: Sequence analysis of human rhinovirus aspirated from the nasopharynx of patients with relapsing-remitting MS. Mult Scler 2009;15:437-442.
19.
von Herrath MG, Oldstone MB: Virus-induced autoimmune disease. Curr Opin Immunol 1996;8:878-885.
20.
Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S: Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001;344:319-326.
21.
Martínez-Sernández V, Figueiras A: Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production. J Neurol 2013;260:1951-1959.
22.
Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, et al: A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 1997;48:312-314.
23.
Westerlind H, Ramanujam R, Uvehag D, Kuja-Halkola R, Boman M, Bottai M, et al: Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain 2014;137:770-778.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.